Research programme: nitric oxide synthase type II inhibitors - DSX Therapeutics
Alternative Names: Anti-iNOS monoclonal antibodies; aSeptiMab®; DSX A; DSX D; DSX I; iNOS inhibitors - DSX TherapeuticsLatest Information Update: 16 Jul 2016
At a glance
- Originator DSX Therapeutics LLC
- Class Monoclonal antibodies
- Mechanism of Action Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Sepsis